This table presents computed estimates for age-specific 5-year overall survival (%) in patients with resected colon cancer with/without 5FU-based adjuvant chemotherapy. There is a section for Low grade and a section for High grade.
Fluorouracil- (FU-) based adjuvant therapy is an established therapy for patients with resected high-risk colon cancer. This tool provides the results from a pooled analysis of 3302 patients from seven randomised trials and compares the magnitude of adjuvant therapy benefit across specific subgroups.
A pooled analysis of adjuvant chemotherapy trials for patients with resected colon cancer was performed to quantify the benefit of 5FU-based chemotherapy for predefined clinical and pathologic subgroups. The table below provides individualized estimates of baseline prognosis and adjuvant-therapy benefit based on T stage, nodal status and grade.
Using the end point of 5-year DFS, the model was evaluated for discriminating ability, calibration and over-fitting. The calibration of the model was assessed by comparing the predicted 5-year DFS rates for surgery alone and for surgery plus adjuvant therapy with the corresponding observed or Kaplan-Meier estimate probabilities.